Aspire Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of a Special Meeting of Stockholders held on April 10, 2026. Aspire Biopharma Holdings, Inc. (ASBP), an emerging growth company incorporated in Delaware, convened the meeting to vote on critical corporate governance and capital structure matters.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the outcomes of shareholder votes regarding capital structure adjustments.
Material Changes and Voting Results
Stockholders approved five key proposals at the Special Meeting:
- Reverse Stock Split Proposal: Approved amendments to the Charter to effect a reverse split of issued and outstanding shares at a ratio between 1-for-5 and 1-for-500, to be determined by the Board within one year.
- Votes For: 2,096,356
- Votes Against: 582,185
- Votes Abstain: 12,852
- Series A Preferred Issuance Proposal: Authorized the issuance of shares upon conversion of Series A Convertible Preferred Stock, including amounts exceeding 19.99% of outstanding common stock, and established a floor price for conversion to comply with Nasdaq Rule 5635(d).
- Votes For: 1,466,141
- Votes Against: 203,756
- Votes Abstain: 8,652
- Broker Non-Votes: 1,012,844
- ELOC Issuance Proposal: Approved the issuance of 19.99% or more of common stock pursuant to a Purchase Agreement (ELOC Agreement) with Arena Business Solutions Global SPC II, Ltd., dated November 11, 2025.
- Votes For: 1,469,985
- Votes Against: 203,926
- Votes Abstain: 4,638
- Broker Non-Votes: 1,012,844
- Authorized Common Stock Increase Proposal: Approved an amendment to increase authorized common stock from 490,000,000 to 700,000,000 shares.
- Votes For: 1,925,368
- Votes Against: 524,501
- Votes Abstain: 7,403
- Broker Non-Votes: 234,122
- Adjournment Proposal: Approved the authority to adjourn the meeting to solicit additional proxies if necessary to pass the other proposals.
- Votes For: 1,893,737
- Votes Against: 551,855
- Votes Abstain: 11,679
- Broker Non-Votes: 234,122
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the context of the voting proposals. The primary contingency noted is the Board's discretion to determine the exact reverse split ratio and the potential to abandon the amendments if necessary.
Investor Verification Checklist
- Reverse Split Ratio: Verify the specific ratio (1-for-5 to 1-for-500) selected by the Board of Directors in subsequent filings.
- Dilution Impact: Assess the impact of the Series A Preferred conversion and the ELOC Agreement on existing shareholder ownership percentages.
- Nasdaq Compliance: Confirm that the approved measures successfully address Nasdaq listing rule 5635(d) requirements regarding minimum bid price or market value.
- Capital Structure: Monitor the increase in authorized shares to 700,000,000 and its implications for future capital raises.